Publication: Proteomic analysis of Plasmodium falciparum response to isocryptolepine derivative
Issued Date
2019-01-01
Resource Type
ISSN
19326203
Other identifier(s)
2-s2.0-85070420031
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
PLoS ONE. Vol.14, No.8 (2019)
Suggested Citation
Kitiya Rujimongkon, Mathirut Mungthin, Jumreang Tummatorn, Sumate Ampawong, Poom Adisakwattana, Usa Boonyuen, Onrapak Reamtong Proteomic analysis of Plasmodium falciparum response to isocryptolepine derivative. PLoS ONE. Vol.14, No.8 (2019). doi:10.1371/journal.pone.0220871 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/49912
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Proteomic analysis of Plasmodium falciparum response to isocryptolepine derivative
Abstract
© 2019 Rujimongkon et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Drug-resistant strains of malaria parasites have emerged for most of antimalarial medications. A new chemotherapeutic compound is needed for malarial therapy. Antimalarial activity against both drug-sensitive and drug-resistant P. falciparum has been reported for an isocryptolepine derivative, 8-bromo-2-fluoro-5-methyl-5H-indolo[3,2-c]quinoline (ICL-M), which also showed less toxicity to human cells. ICL-M has indoloquinoline as a core structure and its mode of action remains unclear. Here, we explored the mechanisms of ICL-M in P. falciparum by assessing the stage-specific activity, time-dependent effect, a proteomic analysis and morphology. Since human topo II activity inhibition has been reported as a function of isocryptolepine derivatives, malarial topo II activity inhibition of ICL-M was also examined in this study. The ICL-M exhibited antimalarial activity against both the ring and trophozoite stages of P. falciparum. Our proteomics analysis revealed that a total of 112 P. falciparum proteins were differentially expressed after ICL-M exposure; among these, 58 and 54 proteins were upregulated and downregulated, respectively. Proteins localized in the food vacuole, nucleus, and cytoplasm showed quantitative alterations after ICL-M treatment. A bioinformatic analysis revealed that pathways associated with ribosomes, proteasomes, metabolic pathways, amino acid biosynthesis, oxidative phosphorylation, and carbon metabolism were significantly different in P. falciparum treated with ICL-M. Moreover, a loss of ribosomes was clearly observed by transmission electron microscopy in the ICL-M-treated P. falciparum. This finding is in agreement with the proteomics data, which revealed downregulated levels of ribosomal proteins following ICL-M treatment. Our results provide important information about the mechanisms by which ICL-M affects the malaria parasite, which may facilitate the drug development of isocryptolepine derivatives.